Antithymocyte globulin (ATG) therapy is an important treatment alternative for patients with acquired aplastic anemia. The mechanism by which it exerts its effects on hematopoiesis is unknown. In this report, we describe the ability of horse ATG to induce growth and differentiation of normal bone marrow. A single cell suspension of normal human bone marrow was cultured in methylcellulose medium and examined for the growth and maturation after incubation with ATG (10 pug/ml). After 3-4 days of culture, spherical colonies containing mature myeloid elements were found in cultures containing ATG but not in cultures containing medium or preimmunization horse IgG. The addition of 10% colonystimulating factor increased growth by 40%. The number of spherical colonies is not dependent on the presence of macrophages or T lymphocytes. This property of ATG may be relevant to the mechanism behind the hematologic recovery in some patients with acquired aplastic anemia. We also describe the ability of ATG to induce terminal differentiation in the HL60 leukemic cell line. ATG binds to HL60 cells and at concentrations between 10 and 100 pg/mi, 50% of the cells become mature granulocytes, acquire the ability to reduce nitroblue tetrazolium, and lose their proliferative capacity in the clonogenic assay. These new observations of ATG-induced differentiation of normal marrow myeloid elements and terminal differentiation of the HL60 cell line point to different avenues for future search of differentiation-inducing agents.
Antithymocyte globulin (ATG) is a heteroantiserum prepared by immunizing animals with pooled human thymocytes. The only available commercial preparation in the United States, ATGAM, is a concentrate of equine IgG antibody. Other noncommercial preparations using thoracic duct lymphocytes as immunogen are also available in the United States and Europe. Biologic activity is determined by its ability to inhibit sheep erythrocyte rosette formation and delay animal skin graft rejection (1) . The antilymphocyte immunosuppressive properties of ATG have led to its use in ameliorating kidney transplant rejection (2, 3) and in treatment of graftvs.-host disease in allogeneic bone marrow transplant recipients (4, 5) .
The treatment with ATG or other similar preparations has emerged as an important therapy for acquired aplastic anemia since 1978. Autologous hematologic reconstitution occurs in 50-74% of patients receiving these preparations (6, 7) . The mechanism for the hematologic recovery in these responding patients is unknown. Many investigators have postulated a reversal of immunosuppression of hematopoiesis as the probable cause of recovery (6, 8) . This hypothesis is supported by some clinical and laboratory evidence. Other mechanisms probably exist, because many patients with severe aplastic anemia do not demonstrate immune-mediated marrow suppression. Also, successful marrow reconstitution has occurred in 11 of 22 patients with aplastic anemia who received a bone marrow transplant from a genetically identical twin in the absence of any form of immunosuppressive and marrow ablative conditioning regimen (9) .
In an effort to explore other mechanisms for ATG-induced hematopoietic recovery, we examined the effect of ATG on hematopoietic precursor cells. In the present report, we describe the ability of ATG to induce morphological differentiation of human bone marrow cultured in semi-solid medium without mediation via T lymphocytes or macrophages. We also describe the ability of ATG to induce terminal differentiation in the HL60 cell line.
MATERIALS AND METHODS
Human Bone Marrow. After obtaining informed consent, we aspirated normal bone marrow from the posterior iliac crest of donors for allogeneic bone marrow transplantation into preservative-free heparinized syringes. The marrow was forced through a 22-gauge needle, diluted 1:2 in Hanks' balanced salt solution without Ca2+ and Mg2+ (GIBCO), and layered on a Ficoll-diatrizoate gradient (density 1.077-1.080) (Litton Bionetics). Mononuclear cells with occasional mature elements were recovered from the interface and suspended in Iscove's medium (GIBCO) containing 20%o fetal calf serum. Duplicate cultures of 2 x 105 cells in single cell suspension were plated in 1 ml of 0.8% methylcellulose in Iscove's medium supplemented with 30o fetal calf serum, 100 units penicillin, 100 pug of streptomycin, and 2 mM L-glutamine in 35-mm tissue culture dishes. Five to 10% human placental conditioned medium prepared by the method of Schlunk and Schleyer (10) was added as a source of colony-stimulating factor (CSF). ATG at various concentrations (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) Cells were suspended at a concentration of 1 x 105 per ml and incubated with various concentrations ofATG for 6 days, at which time the control cultures began to deteriorate. Cells were harvested daily for morphologic examination and viability by using trypan blue exclusion. After 6 days of culture, cells were harvested for cytofluorograph analysis, nitroblue tetrazolium reduction (NBT), and were assayed for clonogenic potential.
Antithymocyte Globulin. ATGAM (Upjohn) lot 17,924 was used in all experiments. Preimmunization horse IgG was also tested for its activity on human bone marrow and HL60 cells. In selected experiments, ATGAM was extensively absorbed with peripheral blood lymphocytes (five absorptions with 107 cells each at 40C for 1 hr).
NBT Reduction. Cells at a concentration of 2 x 106 per ml were incubated for 20 min in an equal volume of 0.4% NBTZ (Sigma) dissolved in Hanks' balanced salt solution containing 400 Ag of freshly diluted phorbol 12 
RESULTS
Morphologic Changes of Human Bone Marrow Induced by ATG. Single cell suspensions of human bone marrow cells were cultured in methylcellulose medium containing 5-10% CSF. In the presence of 10 ,ug of ATG per ml, tight spherical colonies developed from 1-, 2-, 4-, and 8-cell stages to 20-60 cells per colony after 3-4 days of culture. These colonies were not observed in cultures containing medium or preimmunization horse IgG (Fig. 1) . In the presence of ATG, colony cells had mature myeloid characteristics (myelocytes, metamyelocytes, bands, neutrophils, and sometimes a large Proc. NatL Acad. Sci. USA 82 (1985) * : . . . number of eosinophils (Figs. 2 and 3) . Control cultures contained neither tight spherical colonies nor mature elements, although occasional small flat colonies characteristic of early colony forming units-granulocytes/macrophages (CFU-GM) were seen in all cultures.
To examine whether these differentiating tight colonies depended on T lymphocytes or macrophages for growth, T cells and macrophages were removed from normal marrow by treatment with monoclonal antibodies and complement. As seen in Table 1 age of 50-60 cells per colony), suggesting that prostaglandin E (produced by macrophages in culture) may be a negative regulator of cell proliferation of the spherical colony (12) .
When lymphocytes were removed, the number of colonies decreased, although not significantly (Table 1 ). To investigate further the role of lymphocytes, we looked at spherical colonies induced by ATG that had been absorbed with lymphocytes. The number and size of colonies were increased over the controls (data not shown), suggesting that the ATG preparation may contain an inhibitor(s) of colony formation, removable by absorption with lymphocytes. The presence of lymphocytes in the crude marrow similarly may serve to reduce the concentration of the inhibitor, giving better colony growth. Alternatively, ATG may stimulate lymphocytes contained in the marrow aspirate to produce a growth-promoting factor, which in turn increases the number of colonies.
Spherical colony formation is dependent on the presence of ATG. Colonies were regularly seen with or without the addition of CSF, although CSF acts synergistically to promote spherical colony growth induced by ATG (40% increase) as seen in Fig. 4 (average of 2 experiments) .
It is postulated that cells induced to differentiate in the presence of ATG are more mature than CFU-GM precursors, partly because of the brieftime requirement for differentiated colonies to occur (3) (4) days as compared to 6-7 days for CFU-GM) and partly because CFU-GM colonies simultaneously exist in culture and are readily recognizable by their appearance. Furthermore, CFU-GM colony growth approaches its peak at -7 days of culture when spherical colonies are dying. Therefore, it was decided to study the effect of ATG on the HL60 leukemic cell line derived from a patient with acute promyelocytic leukemia. In tissue culture, only a small percentage of HL60 cells (<10%) spontaneously differentiate into more mature forms (myelocytes, metamyelocytes, bands, and neutrophils). HL60 cells grown in suspension in the presence of ATG undergo differentiation toward granulocytes. Similar to other differentiation inducers, effects of ATG are time and concentration dependent (Fig. 5) .
When cells are cultured at 1 x 105 cells per ml in the presence of ATG alone, 50-55% of the cells undergo morphological changes toward mature myeloid elements (myelocytes, metamyelocytes, bands, and neutrophils). These changes are more recognizable after 6 days of culture and at an ATG concentration of 10-100 Ag/ml. Differentiation is seen in a small percentage of cells after 48 hr of culture. After 4 days of culture, the differentiated cells are predominantly myelocytes and metamyelocytes, and after 5-6 days the majority resemble segmented neutrophils. The morphological differentiation seen in these cells was further substantiated by studies with NBT dye reduction. NBT, a water soluble dye, is converted to insoluble intracellular blue formazan by phagocytizing neutrophils. After 6 days of culture at concentrations of ATG from 10 to 100 Ag/ml, 35-40o of the HL60 cells reduced NBT as compared to 8% in the control cultures. Although the concentration of ATG for more apparent cell differentiation was found to be between 10 and 100l g/ml, concentrations as low as 4 Itg/ml also induced some differentiation.
To further evaluate ATG-induced terminal differentiation of HL60 cells, the clonogenic potential under the influence of ATG was measured after 6 days of incubation in liquid medium containing variable concentrations of ATG. After each experiment, the cells were washed, resuspended in fresh medium, and 2 x 104 cells were cultured in 0.8% methylcellulose with 10% CSF. Colonies were counted after 7 additional days of culture and the colony number was normalized according to the number of viable cells initially plated in semisolid medium. The results of these experiments are expressed as a percentage of the number of colonies from the ATG pretreated cells divided by the number of colonies in the control group times 100%6 (Fig. 6 ). Cells cultured with concentrations of ATG between 10 and 100 ,tg/ml expressed a 60-80% loss in clonogenic potential, which parallels the concentration range causing morphological differentiation.
The addition of ATG to HL60 cells in liquid culture also resulted in alterations in the rate of cell growth apparent after 48 hr of culture. The proliferative activity of HL60 cells in liquid cultures was reduced or eliminated with concentrations of ATG greater than 10 Ag/ml (Fig. 7) . Concentrations of 1000 Ag/ml produced cell death. However, at concentrations between 10 and 100 ,ug/ml, cell proliferation ceases although cells remain viable over 6 days of culture. 6 days of culture at each concentration of ATG is included in right-hand column. presence of T lymphocytes or macrophages. Our studies also demonstrate that ATG is capable of inducing morphological and functional differentiation toward granulocytes in the human promyelocytic leukemia cell line, HL60. Fifty percent of the HL60 cells grown in suspension with ATG differentiated to mature myeloid elements and acquired the ability to reduce NBT dye. The optimal concentration of ATG for these effects to occur ranged between 10 and 100 ,g/ml. At these concentrations, HL60 cell proliferation decreased and the clonogenic potential of cells incubated with ATG was reduced to 20-40%o of controls. Other compounds capable of inducing terminal differentiation in this cell line, such as retinoic acid, dimethyl sulfoxide, or phorbol esters have been described (13) (14) (15) . ATG as a differentiation inducer is unique: it is an IgG concentrate made against human T-lymphoid cells but it also binds to the membrane of normal marrow and leukemic HL60 cells. To our knowledge, this is the first report of an antibody preparation capable of inducing differentiation of normal marrow precursors as well as the HL60 cell line and it opens new possibilities for the development of a different species of differentiation inducers.
ATG is effective therapeutically in acquired idiopathic aplastic anemia. Our findings of ATG-induced marrow differentiation may be meaningful in explaining its efficacy in this disease. Higher rates of stem cell proliferation have been achieved in mice by depleting the committed progenitor pool (16) . It is possible that increased differentiation of committed progenitors by ATG enhances the patients' stem cell proliferation. If this hypothesis is true for human marrow, there could be considerable potential use for ATG in conditions involving failure of bone marrow differentiation.
